Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 267

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation

Open access
Connolly, Stuart J., Karthikeyan, Ganesan, Ntsekhe, Mpiko, Haileamlak, Abraham, El Sayed, Ahmed, El Ghamrawy, Alaa, Damasceno, Albertino, Avezum, Alvaro, Dans, Antonio M.L., Gitura, Bernard, Hu, Dayi, Kamanzi, Emmanuel R., Maklady, Fathi, Fana, Golden, Gonzalez-Hermosillo, J. Antonio, Musuku, John, Kazmi, Khawar, Zühlke, Liesl, Gondwe, Lillian, Ma, Changsheng, Paniagua, Maria, Ogah, Okechukwu S., Molefe-Baikai, Onkabetse J., Lwabi, Peter, Chillo, Pilly, Sharma, Sanjib K., Cabral, Tantchou T.J., Tarhuni, Wadea M., Benz, Alexander, van Eikels, Martin, Krol, Amy, Pattath, Divya, Balasubramanian, Kumar, Rangarajan, Sumathy, Ramasundarahettige, Chinthanie, Mayosi, Bongani, Yusuf, Salim · 2022 · New England Journal of Medicine

Abstract

BACKGROUND: Testing of factor Xa inhibitors for the prevention of cardiovascular events in patients with rheumatic heart disease-associated atrial fibrillation has been limited. METHODS: , left atrial spontaneous echo contrast, or left atrial thrombus. Patients were randomly assigned to receive standard doses of rivaroxaban or dose-adjusted vitamin K antagonist. The primary efficacy outcome was a composite of stroke, systemic embolism, myocardial infarction, or death from vascular (cardiac or noncardiac) or unknown causes. We hypothesized that rivaroxaban therapy would be noninferior to vitamin K antagonist therapy. The primary safety outcome was major bleeding according to the International Society of Thrombosis and Hemostasis. RESULTS: Of 4565 enrolled patients, 4531 were included in the final analysis. The mean age of the patients was 50.5 years, and 72.3% were women. Permanent discontinuation of trial medication was more common with rivaroxaban than with vitamin K antagonist therapy at all visits. In the intention-to-treat analysis, 560 patients in the rivaroxaban group and 446 in the vitamin K antagonist group had a primary-outcome event. Survival curves were nonproportional. The restricted mean survival time was 1599 days in the rivaroxaban group and 1675 days in the vitamin K antagonist group (difference, -76 days; 95% confidence interval [CI], -121 to -31; P<0.001). A higher incidence of death occurred in the rivaroxaban group than in the vitamin K antagonist group (restricted mean survival time, 1608 days vs. 1680 days; difference, -72 days; 95% CI, -117 to -28). No significant between-group difference in the rate of major bleeding was noted. CONCLUSIONS: Among patients with rheumatic heart disease-associated atrial fibrillation, vitamin K antagonist therapy led to a lower rate of a composite of cardiovascular events or death than rivaroxaban therapy, without a higher rate of bleeding. (Funded by Bayer; INVICTUS ClinicalTrials.gov number, NCT02832544.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2209051

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 267

Metadata

Authors
Connolly, S. J., Karthikeyan, G., Ntsekhe, M., Haileamlak, A., El Sayed, A., El Ghamrawy, A., Damasceno, A., Avezum, A., Dans, A. M. L., Gitura, B., Hu, D., Kamanzi, E. R., Maklady, F., Fana, G., Gonzalez-Hermosillo, J. A., Musuku, J., Kazmi, K., Zühlke, L., Gondwe, L., Ma, C., Paniagua, M., Ogah, O. S., Molefe-Baikai, O. J., Lwabi, P., Chillo, P., Sharma, S. K., Cabral, T. T. J., Tarhuni, W. M., Benz, A., van Eikels, M., Krol, A., Pattath, D., Balasubramanian, K., Rangarajan, S., Ramasundarahettige, C., Mayosi, B., & Yusuf, S.
Venue
New England Journal of Medicine
Published
2022-09-15
Volume
387
Issue
11
Pages
978-988
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4293410833
Cited by
267
References
11
FWCI
34.83
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation. https://app.cochat.ai/papers/10.1056/nejmoa2209051
The paper
Connolly, S. J., Karthikeyan, G., Ntsekhe, M., Haileamlak, A., El Sayed, A., El Ghamrawy, A., Damasceno, A., Avezum, A., Dans, A. M. L., Gitura, B., Hu, D., Kamanzi, E. R., Maklady, F., Fana, G., Gonzalez-Hermosillo, J. A., Musuku, J., Kazmi, K., Zühlke, L., Gondwe, L., . . . Yusuf, S. (2022). Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2209051

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.